NO991192D0 - Middel for behandling av prostatahypertrofi og prostatakreft - Google Patents

Middel for behandling av prostatahypertrofi og prostatakreft

Info

Publication number
NO991192D0
NO991192D0 NO991192A NO991192A NO991192D0 NO 991192 D0 NO991192 D0 NO 991192D0 NO 991192 A NO991192 A NO 991192A NO 991192 A NO991192 A NO 991192A NO 991192 D0 NO991192 D0 NO 991192D0
Authority
NO
Norway
Prior art keywords
prostate
treatment
hypertrophy
prostate cancer
cancer
Prior art date
Application number
NO991192A
Other languages
English (en)
Other versions
NO991192L (no
NO326207B1 (no
Inventor
Juergen Engel
Thomas Reissmann
Ller-Winzen Hilde Riethm
Juergen Rawert
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of NO991192D0 publication Critical patent/NO991192D0/no
Publication of NO991192L publication Critical patent/NO991192L/no
Publication of NO326207B1 publication Critical patent/NO326207B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO19991192A 1996-09-12 1999-03-11 Anvendelse av forbindelsen Cetrorelix for fremstilling av et middel for behandling av prostatahypertrofi og prostatakreft NO326207B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2599096P 1996-09-12 1996-09-12
US4322897P 1997-04-10 1997-04-10
PCT/EP1997/004740 WO1998010781A1 (en) 1996-09-12 1997-09-01 Means for treating prostate hypertrophy and prostate cancer

Publications (3)

Publication Number Publication Date
NO991192D0 true NO991192D0 (no) 1999-03-11
NO991192L NO991192L (no) 1999-04-28
NO326207B1 NO326207B1 (no) 2008-10-20

Family

ID=26700570

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19991192A NO326207B1 (no) 1996-09-12 1999-03-11 Anvendelse av forbindelsen Cetrorelix for fremstilling av et middel for behandling av prostatahypertrofi og prostatakreft

Country Status (29)

Country Link
US (4) US6054432A (no)
EP (1) EP0925069B1 (no)
JP (1) JP2001500500A (no)
KR (1) KR100546235B1 (no)
CN (1) CN1126566C (no)
AR (1) AR009757A1 (no)
AT (1) ATE370743T1 (no)
AU (1) AU738306B2 (no)
BR (1) BR9713197A (no)
CA (1) CA2215015A1 (no)
CZ (1) CZ298738B6 (no)
DE (1) DE69738045T2 (no)
DK (1) DK0925069T3 (no)
EE (1) EE04000B1 (no)
ES (1) ES2289764T3 (no)
HK (1) HK1021937A1 (no)
HU (1) HUP0000261A3 (no)
IL (3) IL128331A0 (no)
IS (1) IS4978A (no)
MX (1) MXPA99002420A (no)
NO (1) NO326207B1 (no)
NZ (1) NZ334540A (no)
PL (1) PL193184B1 (no)
PT (1) PT925069E (no)
RU (1) RU2215537C2 (no)
SK (1) SK286174B6 (no)
TR (1) TR199900556T2 (no)
TW (1) TWI224002B (no)
WO (1) WO1998010781A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
FR2768055A1 (fr) * 1997-09-11 1999-03-12 Synthelabo Utilisation de derives de sulfonanilide pour obtenir un medicament destine au traitement de l'ejaculation retrograde ou de l'aspermie
TW536402B (en) * 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
US7361680B2 (en) * 1999-07-23 2008-04-22 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7129262B2 (en) * 1999-07-23 2006-10-31 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7151100B1 (en) 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7105560B1 (en) 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
EP1203582A4 (en) * 1999-08-09 2005-08-03 Yamanouchi Pharma Co Ltd MEDICINAL COMPOSITIONS FOR THE TREATMENT OF LOWER UROPATHY
DK1955700T3 (da) 1999-09-30 2011-05-23 Harbor Biosciences Inc Terapeutisk behandling af androgenreceptor-betingede lidelser
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
KR100876538B1 (ko) * 2000-08-17 2008-12-31 아에테르나 젠타리스 게엠베하 Ｌｈｒｈ 길항제의 염의 제조방법
DE10040700A1 (de) * 2000-08-17 2002-02-28 Asta Medica Ag Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung
JP2001288115A (ja) * 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
WO2004026116A2 (en) * 2002-09-19 2004-04-01 The Regents Of The University Of California Use of etodoclac to treat hyperplasia
GB0301016D0 (en) * 2003-01-16 2003-02-19 Univ London Treatment of benign prostatic hyperplasia
CA2513575A1 (en) 2003-01-17 2004-08-05 Threshold Pharmaceuticals, Inc. Treatment of benign prostatic hyperplasia using energolytic agents
TWI423943B (zh) * 2006-05-03 2014-01-21 Wisconsin Alumni Res Found Ｎ,ｎ'-雙（２，３-丁二烯基）-１，４-丁二胺之用途及包含ｎ,ｎ'-雙（２，３-丁二烯基）-１，４-丁二胺的醫藥組成物
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
US10585101B2 (en) 2016-03-10 2020-03-10 Wavesense, Inc. Prostatic liquid biopsy for the detection of prostate cancer and benign prostatic hyperplasia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU199694B (en) * 1988-05-10 1990-03-28 Innofinance Altalanos Innovaci Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives
DE3918543A1 (de) * 1989-06-07 1990-12-13 Boehringer Mannheim Gmbh Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hypertrophie
IL101245A0 (en) * 1991-03-20 1992-11-15 Merck & Co Inc Pharmaceutical compositions for the treatment of prostatic cancer
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer

Also Published As

Publication number Publication date
NO991192L (no) 1999-04-28
US6300313B1 (en) 2001-10-09
IL128331A0 (en) 2000-01-31
TR199900556T2 (xx) 1999-07-21
EP0925069A1 (en) 1999-06-30
HUP0000261A3 (en) 2001-03-28
WO1998010781A1 (en) 1998-03-19
NO326207B1 (no) 2008-10-20
EP0925069B1 (en) 2007-08-22
AU738306B2 (en) 2001-09-13
CA2215015A1 (en) 1998-03-12
CZ80899A3 (cs) 1999-11-17
ES2289764T3 (es) 2008-02-01
KR20010029495A (ko) 2001-04-06
SK30199A3 (en) 2000-03-13
SK286174B6 (sk) 2008-04-07
HUP0000261A2 (hu) 2000-10-28
JP2001500500A (ja) 2001-01-16
DE69738045T2 (de) 2008-05-15
KR100546235B1 (ko) 2006-01-26
PL332085A1 (en) 1999-08-30
EE9900121A (et) 1999-10-15
US6054432A (en) 2000-04-25
DE69738045D1 (de) 2007-10-04
IS4978A (is) 1999-02-16
BR9713197A (pt) 2000-04-04
ATE370743T1 (de) 2007-09-15
IL128331A (en) 2010-05-31
CN1126566C (zh) 2003-11-05
AR009757A1 (es) 2000-05-03
US5998377A (en) 1999-12-07
CN1230121A (zh) 1999-09-29
MXPA99002420A (es) 2004-08-27
NZ334540A (en) 2000-07-28
PT925069E (pt) 2007-10-17
PL193184B1 (pl) 2007-01-31
IL189132A0 (en) 2008-06-05
AU4619897A (en) 1998-04-02
RU2215537C2 (ru) 2003-11-10
US6071882A (en) 2000-06-06
TWI224002B (en) 2004-11-21
HK1021937A1 (en) 2000-07-21
DK0925069T3 (da) 2007-10-29
CZ298738B6 (cs) 2008-01-09
EE04000B1 (et) 2003-04-15

Similar Documents

Publication Publication Date Title
NO991192L (no) Middel for behandling av prostatahypertrofi og prostatakreft
NO994069D0 (no) Forbindelser for immunoterapi av prostatacancer og fremgangsmåte for anvendelse derav
NO971015D0 (no) Forbindelser og metoder for behandling av cancer
NO984229D0 (no) Forbindelser og fremgangsmÕter for immunoterapi og immunodiagnose av prostatakreft
NO20004098D0 (no) FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser
NO991955D0 (no) FremgangsmÕte for behandling av hydrokarboner
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
NO20015516D0 (no) Preparater og anvendelser av ET743 for behandling av kreft
NO20012963L (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
NO20002189L (no) Anvendelse av makrolider for behandling av cancer og mukuladegenerasjon
IS5035A (is) Aðferðir til varnar gegn brjóstakrabbameini
NO983512D0 (no) Midler for behandling og forhindring av AIDS
NO994631D0 (no) Fremgangsmaater og sammensetninger for behandling av eggstokkreft
PT984777E (pt) Piperazinas arilsubstituidas uteis no tratamento da hiperplasia benigna da prostata
ID19542A (id) Pengobatan baru
NO20001758D0 (no) Fremgangsmåter og blandinger for behandling av leddgikt
ATE250580T1 (de) Substituierte pyridino-arylpiperazine zur behandlung benigner prostatahyperplasie
NO961113D0 (no) Behandling og forebyggelse av prostatakreft
NO985068D0 (no) Vaksiner for behandling av lymfom og leukemi
NO992561D0 (no) Oppslemmingsbehandlingssystem og oppslemmingsbehandlingsmetode
AU7130696A (en) Combination of beta-interferon for the treatment of prostate cancer
ZA978162B (en) Means for treating prostate hypertrophy and prostate cancer.
AU4402497A (en) Methods and means for the treatment of malignancies
AUPO851597A0 (en) Treatment of prostate cancer
SI0925069T1 (sl) Uporaba Cetrorelix-a za zdravljenje benigne hipertrofije prostate in prostatnega raka

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees